Summary & Overview
HCPCS Q4149: Excellagen, 0.1 cc
HCPCS Level II code Q4149 denotes Excellagen, 0.1 cc, a topical/implantable biologic product used in wound management. As a product-level HCPCS code, Q4149 is used on claims to identify the specific biologic material supplied for tissue repair and wound healing. Nationally, product-specific codes like Q4149 matter for supply tracking, billing transparency, and payer coverage policy development for advanced wound therapies.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used in claims, the clinical context for Excellagen applications, and common payer considerations. The publication provides benchmarks for code utilization and reimbursement patterns where available, summarizes relevant policy and coverage themes affecting biologic wound products, and highlights clinical scenarios in which a 0.1 cc Excellagen unit is typically employed.
The report is designed for revenue cycle leaders, clinicians involved in wound care, and policymakers seeking concise information about product-level HCPCS coding, payer coverage trends, and the clinical role of Excellagen in outpatient wound management. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4149 represents Excellagen, 0.1 cc, a biologic wound care product intended for application in wound management. The service type is a biologic implant or topical biologic agent used in wound healing. The typical site of service is an outpatient wound care clinic, physician office, or ambulatory surgical setting where topical biologic products are applied or implanted for tissue repair.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing soft tissue wound (for example, a diabetic foot ulcer or a full-thickness skin graft donor site) referred to a wound care clinic. The patient presents for evaluation after conservative measures (offloading, dressings, infection control) have failed and persistent granulation tissue or delayed epithelialization is present. A licensed provider (wound care physician, podiatrist, or dermatologist) documents wound size, depth, vascular status, and prior treatments, obtains informed consent, and prepares the sterile field.
The clinical workflow includes wound cleansing and debridement as indicated, measurement and photographic documentation, and application of a small-volume regenerative biologic product, Q4149 (Excellagen, 0.1 cc), directly to the wound bed. The provider may secure the product with an appropriate dressing and schedule follow-up visits for dressing changes and reassessment. Procedural services such as debridement, local anesthesia, or imaging are reported separately using applicable CPT codes. Billing uses the HCPCS Level II code Q4149 for the product administered, with appropriate modifier(s) added to reflect circumstances such as bilateral procedures, unusual difficulty, or the professional/surgical component as required by payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |